Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humira in active ankylosing spondylitis (ATLAS)
NCT00195819Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Dec 2003
- Primary completion
- Oct 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Adalimumab Arm with Placebo Arm (2 arms). Primary endpoints: Assessments of Ankylosing Spondylitis 20 Response at 12 weeks and Modified Stoke Ankylosing Spondylitis Spine Score at 104 weeks. Started Dec 2003; status: completed.
02
Drugs
Trudexa
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT00195819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00195819.